DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Clinical trial NCT07544654 · RECRUITING
Trial details
- NCT number
- NCT07544654
- Sponsor
- Boehringer Ingelheim
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-10
- Primary completion
- 2029-12-13
- Enrollment
- 390
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.